ten23 health Opens New Office in Tokyo
The expansion of the Swiss CDMO’s activities into the Asia Pacific area marks a significant milestone in its global growth and means it will be able to better serve pharma and biotech companies companies across the region.
Swiss-based, human-centric and sustainable strategic partner for pharma and biotech companies, ten23 health, is expanding its commercial activities in the Asia-Pacific (APAC) region by opening a new office in Tokyo, Japan. The strategic move, which was announced by the company in an April 16, 2026 press release, marks a growth milestone and strengthens ten23 health’s ability to better serve pharma and biotech companies in the APAC area (1).
Japan is reported to be the world’s third largest pharmaceutical market (2), and is expected to experience continued compound annual growth of around 6.4% over the next seven years (3). “We are excited to establish a presence in Japan, one of the world’s leading countries for pharmaceuticals and biotechnology innovation,” said Hanns-Christian Mahler, Chief Enablement Officer, ten23 health, in a company press release (1).
Additionally, as part of the expansion plans, ten23 health has appointed Noriko Utsumi as the Business Development Director for Japan and the broader Asia-Pacific region. Utsumi will draw upon her extensive experience within the life sciences industry to build up client relationships and expand ten 23 health’s commercial activities within the APAC area.
“I am thrilled to join ten23 health at such an exciting time,” added Utsumi in the press release (1). “The company’s commitment to quality, innovation, and client-centric solutions, and the alignment of Swiss and Japanese quality, makes it uniquely positioned to support the growing needs of the Asian market. I look forward to contributing to its expansion and building long-term partnerships in the region.”
The new office, located in Japan, represents ten23 health’s first physical presence in the APAC region and highlights the company’s ambition to become a global partner for pharma and biotech companies.
References
ten23 health. ten23 health Expands its Commercial Activities into the APAC Area Opening Office in Japan. Press Release, April 14, 2026.
CMIC. Top 5 Reasons Emerging and Early-Stage Biopharma Should Consider the Japan Market. CMIC Resources, en.cmicgroup.com (accessed April 17, 2026).
Grand View Research. Japan Biopharmaceutical Market Size & Outlook, 2026–2033. Market Research Report, grandviewresearch.com (accessed April 17, 2026).